共 50 条
Implications of VIP and PACAP in Parkinson's Disease: What do we Know So Far?
被引:10
|作者:
Oliveira de Souza, Filipe Resende
[1
]
Ribeiro, Fabiola Mara
[2
]
d'Almeida Lima, Patricia Maria
[1
]
机构:
[1] Univ Fed Sao Joao del Rei, Dept Nat Sci, Lab Immunol & Microbiol, Praca Dom Helvecio 74, BR-36301160 Sao Joao Del Rei, MG, Brazil
[2] Univ Fed Minas Gerais, Dept Biochem & Immunol, Lab Neurobiochem, Ave Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil
关键词:
Vasoactive intestinal peptide (VIP);
pituitary adenylate-cyclase activating polypeptide (PACAP);
Parkinson's disease;
neuroinflammation;
oxidative stress;
neuropeptides;
neurodegenerative disease;
VASOACTIVE-INTESTINAL-PEPTIDE;
CYCLASE-ACTIVATING POLYPEPTIDE;
SH-SY5Y CELLS IMPLICATION;
ADENYLATE-CYCLASE;
TNF-ALPHA;
T(H)17 CELLS;
MOUSE MODEL;
RECEPTOR;
BRAIN;
MICROGLIA;
D O I:
10.2174/0929867327666200320162436
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Background: Parkinson's disease is one of the most common neurodegenerative disorders and although its aetiology is not yet fully understood, neuroinflammation has been identified as a key factor in the progression of the disease. Vasoactive intestinal peptide and pituitary adenylate-cyclase activating polypeptide are two neuropeptides that exhibit anti-inflammatory and neuroprotective properties, modulating the production of cytokines and chemokines and the behaviour of immune cells. However, the role of chemokines and cytokines modulated by the endogenous receptors of the peptides varies according to the stage of the disease. Methods: We present an overview of the relationship between some cytokines and chemokines with vasoactive intestinal peptide, pituitary adenylate cyclase activating polypeptide and their endogenous receptors in the context of Parkinson's disease neuroinflammation and oxidative stress, as well as the modulation of microglial cells by the peptides in this context. Results: The two peptides exhibit neuroprotective and anti-inflammatory properties in models of Parkinson's disease, as they ameliorate cognitive functions, decrease the level of neuroinflammation and promote dopaminergic neuronal survival. The peptides have been tested in a variety of in vivo and in vitro models of Parkinson's disease, demonstrating the potential for therapeutic application. Conclusion: More studies are needed to establish the clinical use of vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide as safe candidates for treating Parkinson's disease, as the use of the peptides in different stages of the disease could produce different results concerning effectiveness.
引用
收藏
页码:1703 / 1715
页数:13
相关论文